Montara Therapeutics

Founded 2022 · CIK 0002008775 · Biotech · Private

RNA-targeted small molecule therapeutics for neuromuscular and rare genetic diseases

montaratx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$28M
2 Form D · Mar 2025
19 months since last filing
Contracts
—
No federal contracts on record
Patents
13
0 granted · 13 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$8,000,011
Private capital raisedForm D · SEC$19,999,995
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2363ACRIGEN BIOSCIENCES, INC.—$775K
2364MARCH BIOSCIENCES INC—$22M
2365Biodesy LLC—$350K
2366Montara Therapeutics—$28M
2367VST BIO Corp—$29M
2368Propagenix Inc—$2.3M
2369Merida Biosciences——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 8 related persons
  • Randall ChinExecutive Officer
  • Nicholas HertzDirector · Executive Officer · Promoter
  • Zachary HillExecutive Officer
  • Dirk LangdorfDirector
  • Max LebovitzExecutive Officer
  • Rishi RakhitExecutive Officer
  • Seth StrattonDirector
  • Troy WilsonDirector

Patents

USPTO · 0 granted of 13
  • Central Nervous System-selective Activity Of Lxr Agonistsapplication
  • Central Nervous System-selective Activity Of LRRK2 Inhibitorsapplication
  • Central Nervous System-selective Activity Of Everolimusapplication
  • Peripheral Blockers For Central Nervous System-selective Drug Activityapplication
  • Central Nervous System-selective Activity Of Lxr Agonistsapplication
  • Central Nervous System-selective Activity Of LRRK2 Inhibitorsapplication
  • Central Nervous System-selective Activity Of Everolimusapplication
  • Peripheral Blockers For Central Nervous System-selective Drug Activityapplication
  • Central Nervous System-selective Activity Of LRRK2 Inhibitorsapplication
  • Central Nervous System-selective Activity Of Everolimusapplication
  • Central Nervous System-selective Activity Of Tacrolimusapplication
  • Peripheral Blockers For Central Nervous System-selective Drug Activityapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.